Send to

Choose Destination
J Infect Dis. 2016 Feb 15;213(4):611-7. doi: 10.1093/infdis/jiv472. Epub 2015 Sep 25.

Humoral Immunity to Cytomegalovirus Glycoprotein B in Patients With Breast Cancer and Matched Controls: Contribution of Immunoglobulin γ, κ, and Fcγ Receptor Genes.

Author information

Department of Microbiology and Immunology, Medical University of South Carolina, Charleston.
Department of Biostatistics, Virginia Commonwealth University, Richmond.
Division of Epidemiology, National Cancer Center, Tokyo.
Department of Surgery, Nagano Matsushiro General Hospital, Japan.
Nikkei Disease Prevention Center, São Paulo, Brazil.
Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo.


Increasing evidence implicates human cytomegalovirus (HCMV) in the etiopathogenesis of breast cancer. Antibodies to this virus in patients with breast cancer have been reported, but no large-scale studies have been conducted to determine whether the antibody levels differ between patients and matched controls. Using specimens from a large (1712 subjects) multiethnic case-control study, we aimed to determine whether the levels of antibodies to the HCMV glycoprotein B (gB) differed between patients and controls and whether they were associated with particular immunoglobulin γ marker (GM), κ marker (KM), and Fcγ receptor (FcγR) genotypes. A combined analysis showed that anti-gB immunoglobulin G antibody levels were higher in healthy controls than in patients (P < .0001). Stratified analyses showed population-specific differences in the magnitude of anti-gB antibody responsiveness and in the contribution of particular GM, KM, and FcγR genotypes to these responses. These findings may have implications for HCMV-based immunotherapy against breast cancer and other HCMV-associated diseases.


FcγR genes; GM/KM allotypes; glycoprotein B; human cytomegalovirus; humoral immunity

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center